Key Takeaways
- • Kotak Alternate Asset Managers invests Rs 1,445 crore through its Kotak Strategic Situations Fund II to facilitate Matrix Pharma's acquisition of Viatris' active pharmaceutical ingredients (API) business.
- • The transaction positions Matrix as the second-largest Indian API player with global leadership in antiretroviral (ARV) APIs, leveraging Viatris' R&D capabilities including 185+ scientists and 600+ DMF filings.
- • Matrix gains regulatory approvals for US and EU markets and access to established relationships with major global pharmaceutical companies, enabling accelerated market penetration.
- • Kotak Alt's investment will support Matrix's organic growth through third-party sales expansion and selective inorganic growth opportunities within the pharmaceutical CDMO space.
- • India's position as the world's third-largest API manufacturer, combined with cost-competitive manufacturing and chemistry capabilities, provides strategic foundation for Matrix's global expansion ambitions.
Summary
Kotak Alternate Asset Managers announced a Rs 1,445 crore equity investment on June 11, 2024, to facilitate Matrix Pharma Private Limited's acquisition of Viatris' API business. The transaction was executed through Kotak Alt's Kotak Strategic Situations Fund II, a dedicated alternative asset vehicle focused on strategic situations in key sectors.
The acquisition represents a significant consolidation move within India's pharmaceutical manufacturing ecosystem. Upon completion, Matrix will emerge as the second-largest Indian API manufacturer while achieving global leadership specifically in antiretroviral (ARV) APIs. The deal provides Matrix access to Viatris' substantial R&D infrastructure, including a team of over 185 scientists and more than 600 Drug Master File (DMF) filings—critical regulatory documentation that accelerates product approvals. Equally valuable, Matrix inherits Viatris' regulatory approvals for both US and EU markets, along with established commercial relationships with major global pharmaceutical companies.
According to Srini Sriniwasan, Managing Director of Kotak Alternate Asset Managers, the investment demonstrates the firm's deal sourcing and structuring capabilities within pharmaceuticals. "This acquisition of a significant business, along with key incumbent management joining us, showcases Kotak Alt's strong deal sourcing and structuring capabilities," Sriniwasan stated, emphasizing the firm's ability to build "a robust API platform that we can support through both organic and inorganic growth."
Eshwar Karra, CEO of Kotak Strategic Situations Fund, characterized the investment as a bet on India's competitive manufacturing advantages. "India is the third largest API manufacturer in the world, known for its chemistry capabilities and cost-competitive manufacturing," Karra noted, positioning the backing of Matrix's management team as aligned with India's broader pharmaceutical export ambitions.
Kotak Alt's capital will support Matrix's dual growth strategy: strengthening third-party sales channels for existing products and selectively pursuing inorganic opportunities within the contract development and manufacturing organization (CDMO) sector, where consolidation dynamics remain active.
The acquisition represents a significant consolidation move within India's pharmaceutical manufacturing ecosystem. Upon completion, Matrix will emerge as the second-largest Indian API manufacturer while achieving global leadership specifically in antiretroviral (ARV) APIs. The deal provides Matrix access to Viatris' substantial R&D infrastructure, including a team of over 185 scientists and more than 600 Drug Master File (DMF) filings—critical regulatory documentation that accelerates product approvals. Equally valuable, Matrix inherits Viatris' regulatory approvals for both US and EU markets, along with established commercial relationships with major global pharmaceutical companies.
According to Srini Sriniwasan, Managing Director of Kotak Alternate Asset Managers, the investment demonstrates the firm's deal sourcing and structuring capabilities within pharmaceuticals. "This acquisition of a significant business, along with key incumbent management joining us, showcases Kotak Alt's strong deal sourcing and structuring capabilities," Sriniwasan stated, emphasizing the firm's ability to build "a robust API platform that we can support through both organic and inorganic growth."
Eshwar Karra, CEO of Kotak Strategic Situations Fund, characterized the investment as a bet on India's competitive manufacturing advantages. "India is the third largest API manufacturer in the world, known for its chemistry capabilities and cost-competitive manufacturing," Karra noted, positioning the backing of Matrix's management team as aligned with India's broader pharmaceutical export ambitions.
Kotak Alt's capital will support Matrix's dual growth strategy: strengthening third-party sales channels for existing products and selectively pursuing inorganic opportunities within the contract development and manufacturing organization (CDMO) sector, where consolidation dynamics remain active.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.